Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up
negativeNegative
AI Analysis
Summary
Caribou Biosciences is ending R&D activities and cutting staff as it faces a financing freeze. The CAR-T biotech, which went public in 2021 with backing from Novartis, AbbVie, and Pfizer, is experiencing significant operational challenges.
Outcome Details
Caribou Biosciences ending R&D activities and slashing staff due to financing freeze
Importance:8/10
Sentiment:
-0.95
R&D closureworkforce reductionfinancing crisisCAR-Tpublic company
Read the original article
Published by BioSpace on October 7, 2026 12:05 PM